GET DAILY SIGNALSClearPoint Neuro (CLPT): Can the Stock Climb Back to $25?
Key Takeaways
- The selected price target is $25, roughly 60% above recent trading levels near $15 and below the stock's 52-week high of $30.10.
- Wall Street consensus is a Strong Buy, with analyst price targets ranging from $22 to $30 and averages clustered near $23.50 to $25.
- The strongest bullish catalysts are expanding biopharma partnerships, notably uniQure's (QURE) Huntington's disease program and Aspen Neuroscience's Parkinson's cell therapy.
- Key obstacles include persistent net losses, negative cash flow, a recent revenue guidance cut, and elevated short interest.
- Reaching $25 likely depends on revenue reacceleration and tangible progress from gene therapy partners rather than valuation expansion alone.
Company Snapshot
ClearPoint Neuro develops and commercializes the ClearPoint system, which allows surgeons to conduct minimally invasive brain procedures under direct MRI guidance during the operation. The platform consists of hardware like a head-fixation frame and workstation, plus disposables such as the SmartFrame trajectory device and SmartFlow cannula. In recent years the company has focused more on supporting neuro cell and gene therapy delivery for a network of over 60 biopharma partners.
Current Trading Position
CLPT trades near $15, for a market capitalization of roughly $467 million. Over the past year the shares have moved sharply, from a low of $8.27 to a high of $30.10, with a beta around 1.27. Trailing twelve-month revenue came in near $42 million, more than 25% higher year over year, yet the company posted a net loss of about $34.6 million. Cash stands at roughly $29 million against $64 million in debt. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Appeal of the $25 Level
The $25 mark aligns closely with published analyst targets. Lake Street Capital keeps a Buy rating and $25 objective, B. Riley Securities lists $30, and Stifel carries $22. The consensus average sits near $23.50 to $25, so $25 represents a logical round-number goal that reflects mainstream expectations over the next twelve months. Importantly, it is not arbitrary—the stock already traded through that level during last year’s rally toward $30.
Potential Drivers Higher
Progress among gene therapy partners remains the clearest catalyst. In mid-2026 shares rose about 32% after uniQure outlined plans for a biologics license application submission for AMT-130 in Huntington’s disease, a move B. Riley referenced when lifting its target from $20 to $30. Separately, partner Aspen Neuroscience earned Regenerative Medicine Advanced Therapy designation from the FDA for its Parkinson’s cell therapy, which could speed review. ClearPoint’s navigation and delivery tools are used in these procedures, so successful commercial adoption by partners could generate more stable, procedure-based revenue.
The company continues to expand its technology reach. It obtained CE Marking for the Velocity Alpha MR high-speed surgical drill system and entered a ten-year focused ultrasound development partnership with Sungkyunkwan University in South Korea. The IRRAS acquisition added the IRRAflow product to the neurosurgery lineup.
Obstacles That Remain
The route to $25 faces several hurdles. ClearPoint stays deeply unprofitable, with negative operating cash flow and ongoing cash burn. Management recently trimmed full-year 2026 revenue guidance to $48 million–$52 million from the prior $52 million–$56 million range, pointing to a focus on higher-return investments. Second-quarter 2026 revenue of about $10.9 million also fell short of consensus estimates.
Sentiment shows caution too. Short interest stands at roughly 14% of shares outstanding, and recent insider activity has tilted toward selling. With no earnings and a price-to-sales ratio above 10, the valuation rests heavily on growth that has yet to fully appear.
Technical Levels Worth Watching
From a technical standpoint, the $15 zone has served as a key battleground, while the prior $30 high sets the main upside reference. In between, $20 and $25 act as psychological markers, with $25 as the primary recovery objective in the near-to-intermediate term. A sustained move above the mid-teens would mark the first step toward rebuilding momentum, while the $8–$9 area remains the lower bound of the range and a meaningful support level.
Enhancing Research with AI Signals
I regularly turn to Tickeron’s AI Daily Buy/Sell Signals when reviewing names like CLPT. The tool scans thousands of stocks and ETFs daily, applying artificial intelligence to technical patterns and market shifts to produce Buy, Sell, or Hold signals. It helps me identify potential entry points and monitor trend changes alongside fundamental work, adding a systematic element to the overall process.
Final Assessment
Moving from current levels to $25 looks plausible yet far from assured. The case rests on analyst support and a pipeline of gene therapy partnerships that could eventually deliver recurring procedure revenue. Counterbalancing factors include ongoing losses, the recent guidance reduction, and a valuation that already prices in substantial future growth. For the target to become realistic, revenue would need to reaccelerate, key partners would need clearer timelines, and the cash position would need to stabilize. Until those elements align, $25 remains an achievable benchmark on paper that ultimately depends on execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CLPT sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for CLPT moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
CLPT broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLPT entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLPT's RSI Oscillator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CLPT as a result. In 76 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for CLPT just turned positive on October 26, 2026. Looking at past instances where CLPT's MACD turned positive, the stock continued to rise in 41 of 54 cases over the following month. The odds of a continued upward trend are 76%.
Following a +10.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 217 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (24.345) is slightly higher than the industry average of (4.142). P/E Ratio (-7.288) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart.
Industry MedicalNursingServices
Advertisement